The Patent Finder

Terms ending in 2027

Array Biopharma Inc.

Every in-force patent on Array Biopharma Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 8,039,639Kinase Inhibitors and Methods of Use Thereof
In force
 · High confidence
Array Biopharma, Inc.In forceHigh confidence
US 9,693,989N4-PHENYL-QUINAZOLINE-4-Amine Derivatives and Related Compounds as Erbb Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases
In force
 · High confidence
Array Biopharma, Inc.In forceHigh confidence
US 9,359,340Hydroxylated and Methoxylated Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors
In force
 · High confidence
Genentech, Inc.In forceHigh confidence
US 8,044,083Kinase Inhibitors and Methods of Use Thereof
In force
 · High confidence
Array Biopharma, Inc.In forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Array Biopharma Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited